|Day Low/High||43.74 / 44.10|
|52 Wk Low/High||36.41 / 46.01|
If you have an appetite for risk, there are buying opportunities.
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.
Stocks were sharply lower at midday in a volatile session to end the week.
This trio enjoys competitive advantages that should serve investors well over the long haul.
The stock has put in a tradable low that can support a respectable rally that could carry into early 2016.
For Wednesday October 28, TheStreet awaits quarterly results from Walgreens Boots Alliance (WBA), Mondelez (MDLZ), Fiat Chrysler (FCAU), Amgen (AMGN), PayPal (PYPL), Buffalo Wild Wings (BWLD) and more.
Eli Lilly has bucked the downtrend in other pharma names, and its chart is pointed higher.
U.S. stocks open sharply higher Wednesday. Wall Street followed a 7.7 percent gain in Japan's Nikkei Stock Index, the biggest percentage gain since October 2008.
Not many, according to filings from Tweedy Browne and Kahn Brothers.
As health-care stocks rally, it's time for politicians to move on.
Deals coming fast and furious in the best group in town.
Whether it's acquiring or the acquired, Mylan is building shareholder value.
Americans are living much longer these days -- and there are a number of ways to invest.
On Wednesday, October 22nd we continue a busy earnings week, with the country's second largest wireless carrier, AT&T Inc.
Federal Reserve Bank of New York, Goldman Sachs, secretly recorded tapes, and a female employee fired -- those are all real life elements from the headlines circulating around Carmen Segarra.
McDonald's and GlaxoSmithKline are fighting against major turns of the tide.
Investors will be tracking Pfizer's earnings when they report first-quarter results on May 5. Expectations are for earnings of $0.55 a share on sales of $12.07 billion.